The Sinopharm vaccine from China, which has just been imported to Indonesia, was declared haram by the Indonesian Ulema Council (MUI) because it contains pork trypsin, aka haram.
SuaraJatim.id – Vaccine Sinopharm of Chinese origin who had just been imported to Indonesia, was declared haram by the Indonesian Ulema Council (MUI) because it contains pork trypsin, aka haram. However, because it is currently in an emergency condition, MUI stated that it can still be used by Muslims in the country.
The head of the MUI Fatwa Commission, Hasanuddin Abdul Fatah, said that this decision had been fatwaed in the MUI plenary meeting on Saturday (1/5/2021) yesterday.
“It is the same as the AstraZeneca vaccine, yes, so (Sinopharm Vaccine) does contain trypsin from pigs, so it is haram. However, it can be used because it is an emergency,” Hasanuddin said when contacted, Monday (3/5/2021).
The agency assessed that current vaccination is an urgent or emergency, so it must be done quickly to control the Covid-19 Pandemic.
Meanwhile related to availability Covid-19 Vaccine which is lawful and holy in the world is not sufficient for the implementation of vaccination in order to realize herd immunity.
“Indeed, the stipulation is that when the halal vaccines are sufficient according to the government’s target, yes, the illegal vaccines are no longer used. But if (the halal vaccines) are still lacking, the haram ones can still be used,” he explained.
Not only that, MUI also realizes that the government does not have the freedom to choose the type of Covid-19 vaccine because of the limited vaccines available, both in Indonesia and at the global level.
Previously, the Food and Drug Administration (BPOM) had also issued an emergency use authorization (EUA) permit for the Covid-19 Sinopharm vaccine with EUA number 2159000143A2 on April 29, 2021.
The Sinopharm vaccine is one of the brands of the Covid-19 vaccine which is intended for independent vaccination programs or the mutual cooperation vaccine which is privately managed.
The results of phase III clinical trials conducted in the United Arab Emirates showed the efficacy of the Sinopharm vaccine reached 78 percent with mild and safe side effects.